Delving into the Latest Updates on Pola Chemical Industries, Inc. with Synapse

Safety evaluation of formulation use containing active ingredient of quasi-drug at microneedle radiofrequency treatment site for the treatment of enlarged facial pores - Safety evaluation of formulation use containing active ingredient of quasi-drug at microneedle radiofrequency treatment site for the treatment of enlarged facial pores

开始日期2024-06-09

申办/合作机构

Pola Chemical Industries, Inc.

JPRN-UMIN000052995

/ SuspendedN/A

Electrical muscle stimulation intervention study with Japanese elderly with sarcopenia or dynapenia: randomized-controlled trial - Electrical muscle stimulation intervention study with Japanese elderly with sarcopenia or dynapenia

开始日期2024-01-09

申办/合作机构

Pola Chemical Industries, Inc.

JPRN-UMIN000052132

/ CompletedN/AIIT

Research on improvement mechanism of solar lentigo - Research on improvement mechanism of solar lentigo

开始日期2023-09-27

申办/合作机构

Pola Chemical Industries, Inc.

100 项与 Pola Chemical Industries, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Pola Chemical Industries, Inc. 相关的专利（医药）

登录后查看更多信息

223

项与 Pola Chemical Industries, Inc. 相关的文献（医药）

2025-03-01·Geriatric Nursing

Association of depression and loneliness with risk of disability among community-dwelling older adults

Article

作者: Tsutsumimoto, Kota ; Nishimoto, Kazuhei ; Ohata, Tomoka ; Kiuchi, Yuto ; Shimada, Hiroyuki ; Misu, Yuka

This study aimed to examine whether the risk of disabilities was reduced among community-dwelling older adults who experienced either depression or loneliness compared with those who experienced both. This sample included 5,005 older adults. Participants were followed for two years from baseline for incidence of disability. They were classified into four groups based on the presence of loneliness and depressive symptoms. The Cox proportional-hazards model, adjusted for confounders, was used to examine their associations with the incidence of disability. The incidence of disability in the comorbid, depression-only, loneliness-only, and robust groups was 11.6 %, 6.9 %, 5.3 %, and 4.2 %, respectively. The depression-only (HR 0.59, 95 % CI 0.36‒0.96), loneliness-only (HR 0.44, 95 % CI 0.31‒0.62), and robust groups (HR 0.34, 95 % CI 0.25‒0.46) had a significantly lower risk of disability compared with the comorbid group. It was concluded that alleviating depression or loneliness may reduce the risk of future disability.

2025-01-15·The Journal of Japan Society for Laser Surgery and Medicine

Analysis of Skin Structure and Blood Vessel Network Using Photoacoustic and High-frequency Ultrasound Microscopy

作者: Ida, Taiichiro ; Mizukoshi, Koji

2024-12-20·Journal of Society of Cosmetic Chemists of Japan

Basics and Applications of Pickering Emulsion

作者: Nakatani, Akihiro

100 项与 Pola Chemical Industries, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Pola Chemical Industries, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月12日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

2

5

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

克林霉素磷酸酯/过氧苯甲酰 ( 50S subunit )	寻常痤疮更多	批准上市
卢立康唑 ( fungal CYP51A1 )	足癣更多	批准上市
18F-RP-170	心肌缺血更多	终止
多拉达唑	食管癌更多	无进展
PR-001337	哮喘更多	无进展